ReviewArchives of endocrinology and metabolism
Determinants of morbidities and mortality in acromegaly.
Review in Archives of endocrinology and metabolism. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 35 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
35 citing papers in PubMed, 1 synthesis or guideline pooled it, 65 citations in OpenAlex.
- Risk of cerebrovascular and cardiovascular events in acromegaly: a systematic review and meta-analysis.Endocrine · 2026Pooled it
- Population Pharmacokinetic Analysis of an Octreotide Depot (CAM2029) in the Treatment of Acromegaly.Clinical pharmacokinetics · 2025Trial
- Acromegaly and Metabolic Dysfunction-Associated Steatotic Liver Disease: Clinical and Therapeutic Implications.Current obesity reports · 2026Review
- Impact of Nutrition on Somatotroph Axis: A Potential Role in Acromegaly and Its Cardiovascular Risk?Journal of the Endocrine Society · 2026Review
- Acromegaly treatment and bone: a bidirectional relationship.Pituitary · 2025Review
- Importance of the early diagnosis of acromegaly. Evolution of mandibular growth and dental occlusion in a case with a late diagnosis.Journal of clinical and experimental dentistry · 2025Review
- Copeptin and Mid-Regional Proadrenomedullin Are Not Useful Biomarkers of Cardiometabolic Disease in Patients with Acromegaly-A Preliminary Study.Biomedicines · 2025Article
- Acromegaly: diagnostic challenges and individualized treatment.Expert review of endocrinology & metabolism · 2025Review
- Personalized Medicine in Acromegaly: The ACROFAST Study.The Journal of clinical endocrinology and metabolism · 2024Article
- Diagnostic, therapeutic, and prognostic characteristics of patients with acromegaly according to tumor size at diagnosis.Pituitary · 2024Observational
- ACROMORFO study: gait analysis in a cohort of acromegalic patients.Journal of endocrinological investigation · 2024Article
- Predicting Response to Medical Treatment in Acromegaly via Granulation Pattern, Expression of Somatostatin Receptors Type 2 and 5 and E-Cadherin.International journal of molecular sciences · 2024Article
- Importance of 24 h ambulatory blood pressure monitoring in patients with acromegaly and correlation with cardiac magnetic resonance findings.Pituitary · 2023Article
- Article
- Endoscopic endonasal approach for acromegaly: surgical outcomes using 2018 consensus criteria for remission.Archives of endocrinology and metabolism · 2023Article
- miR-383-5p, miR-181a-5p, and miR-181b-5p as Predictors of Response to First-Generation Somatostatin Receptor Ligands in Acromegaly.International journal of molecular sciences · 2023Article
- Preoperative and postoperative blood testosterone levels in patients with acromegaly: a prospective study.Frontiers in endocrinology · 2023Article
- Associations between paraclinical parameters, symptoms and quality of life in patients with acromegaly: a cross sectional study.Journal of patient-reported outcomes · 2022Article
- Global psychological assessment with the evaluation of life and sleep quality and sexual and cognitive function in a large number of patients with acromegaly: a cross-sectional study.European journal of endocrinology · 2022Article
- Impact of the diagnostic delay of acromegaly on bone health: data from a real life and long term follow-up experience.Pituitary · 2022Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Acromegaly is a systemic disease associated with increased morbidity, presenting cardiovascular, metabolic, respiratory, neoplastic, endocrine, articular and bone complications. Most of these comorbidities can be prevented or delayed with adequate disease treatment and, more recent studies with the use of modern treatments of acromegaly, have shown a change in the severity and prevalence of these complications. In addition, acromegaly is associated with increased mortality, but recent studies (especially those published in the last decade) have shown a different scenario than older studies, with mortality no longer being increased in adequately controlled patients and a change in the main cause of death from cardiovascular disease to malignancy. In this review, we discuss this changing face of acromegaly summarizing current knowledge and evidence on morbimortality of the disease. Arch Endocrinol Metab. 2019;63(6):630-7.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.